ALK-Abelló A/S (AKABY) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Horsholm, Denmark. El CEO actual es Carsten Hellmann.
AKABY tiene fecha de IPO 2013-09-05, 2,566 empleados a tiempo completo, cotiza en el Other OTC.
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
